Key result
Oral terbutaline is associated with ~7% higher heart rate and decreased HRV in feline subclinical HCM.
Why the study?
The utility of ambulatory electrocardiography to evaluate cats with subclinical hypertrophic cardiomyopathy for arrhythmias and heart rate variability is not well defined but may provide risk stratification information.
Does ambulatory electrocardiography with terbutaline stress testing reveal differences in ectopy and heart rate variability in cats with subclinical hypertrophic cardiomyopathy compared to healthy controls?
Observational (n=23)
Single-blind
No
Does ambulatory electrocardiography with terbutaline stress testing reveal differences in ectopy and heart rate variability in cats with subclinical hypertrophic cardiomyopathy compared to healthy controls?
Absolute Event Rate: 209.2% vs 195%
p-value: p=<0.0001
In a feline model of subclinical HCM, ambulatory ECG with terbutaline stress testing revealed increased heart rate variability and genotype-associated ectopy compared to healthy controls.
Terbutaline alters HR dynamics in feline subclinical HCM; hypothesis-generating for ambulatory ECG stress testing, with no clinical implications yet.
The utility of ambulatory electrocardiography (AECG) to evaluate cats with subclinical hypertrophic cardiomyopathy (HCM) for arrhythmias and heart rate variability (HRV) is not well defined but may provide information regarding risk stratification. This prospective study used AECG to evaluate ectopy and HRV in subclinical HCM cats compared to healthy controls and is the first to implement a pharmacologic cardiac stress test. Twenty-three purpose-bred, Maine coon cross cats (16 HCM, 7 control) underwent 48-h of continuous AECG. Terbutaline (0.2-0.3 mg/kg) was administered orally at 24 and 36 h. Heart rate, ectopy frequency and complexity and HRV parameters, including standard deviation of normal R-R intervals (SDNN), were compared pre-terbutaline and post-terbutaline and across phenotype, genotype and sex. Genotype for an HCM-causative mutation was significantly associated with the frequency of supraventricular (P = 0.033) and ventricular (P = 0.026) ectopy across all cats. Seven HCM cats and zero healthy cats had a sinus arrhythmia. Mean heart rate was significantly higher post-terbutaline (p < 0.0001). HCM cats had significantly greater HRV compared to controls (SDNN: p = 0.0006). Male cats had significantly higher HRV (SDNN: p = 0.0001) and lower mean heart rates (p = 0.0001). HRV decreased post-terbutaline (SDNN: p = 0.0008) and changes in HRV observed between sexes were attenuated by terbutaline.
No takes yet. Share an insight, caveat, or question.
Walker et al. (2022) conducted an observational in Subclinical hypertrophic cardiomyopathy (n=23). Terbutaline vs. Pre-terbutaline (resting state) was evaluated on Mean heart rate (bpm) (p=<0.0001). Oral terbutaline administration significantly increased mean heart rate from 195.0 to 209.2 bpm and decreased heart rate variability in cats with subclinical hypertrophic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: